Both authors contributed equally to this work.
The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor
Article first published online: 5 MAR 2003
Alimentary Pharmacology & Therapeutics
Volume 17, Issue 4, pages 489–501, February 2003
How to Cite
Alsalameh, S., Burian, M., Mahr, G., Woodcock, B. G. and Geisslinger, G. (2003), The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology & Therapeutics, 17: 489–501. doi: 10.1046/j.1365-2036.2003.01460.x
- Issue published online: 5 MAR 2003
- Article first published online: 5 MAR 2003
- Accepted for publication 15 November 2002
Cyclo-oxygenase-2-selective inhibitors produce less gastric damage than conventional non-steroidal anti-inflammatory drugs. Valdecoxib is a new orally administered cyclo-oxygenase-2-selective inhibitor, recently approved for use in osteoarthritis, rheumatoid arthritis and primary dysmenorrhoea in the USA. The drug has been evaluated in more than 60 clinical studies involving more than 14 000 patients and healthy volunteers. The analgesic efficacy of valdecoxib at a dose of 10 mg once daily in both osteoarthritis and rheumatoid arthritis is superior to that of placebo and similar to that of traditional non-steroidal anti-inflammatory drugs. Valdecoxib is effective in single doses of up to 40 mg for the alleviation of acute menstrual pain and has a rapid onset of action (within 30 min) and a long duration of analgesia (up to 24 h). Valdecoxib is well tolerated and has safety advantages compared with traditional non-steroidal anti-inflammatory drugs in terms of less gastrointestinal toxicity and a lack of an effect on platelet function. The incidence of adverse effects involving the kidney (fluid retention, oedema and hypertension) is similar to that of non-selective, non-steroidal anti-inflammatory drugs.